NCT02387307View on ClinicalTrials.gov

A Study of rSIFN-co in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Carcinoma, Non-Small-Cell LungCarcinoma, Renal CellMelanomaCarcinoma, HepatocellularColon Cancer
Interventions
DRUG

rSIFN-co

rSIFN-co is a drug developed by Sichuan Huiyang Life Science and Technology Corporation for the treatment of solid tumors especially in non-small cell lung cancer and other tumor types. The study comprises of 2 stages: the dose-escalation stage and dose expansion stage.

Trial Locations (1)

169610

National Cancer Centre Singapore, Singapore

All Listed Sponsors
lead

Sichuan Huiyang Life Science and Technology Corporation

INDUSTRY

NCT02387307 - A Study of rSIFN-co in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter